The therapy of idiopathic pulmonary fibrosis: what is next?
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease, characterised by progressive scarring of the lung and associated with a high burden of disease and early death. The pathophysiological understanding, clinical diagnostics and therapy of IPF have signi...
Main Authors: | Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, Nicolas Kahn, Veronika Müller, Michael Kreuter |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2019-09-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/28/153/190021.full |
Similar Items
-
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
by: Claudia Valenzuela, et al.
Published: (2020-01-01) -
Idiopathic Pulmonary Fibrosis (IPF): An Overview
by: Shaney L. Barratt, et al.
Published: (2018-08-01) -
Management of idiopathic pulmonary fibrosis: selected case reports
by: Michael Kreuter, et al.
Published: (2014-06-01) -
Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review
by: Conal Hayton, et al.
Published: (2019-01-01) -
Cell Therapy in Idiopathic Pulmonary Fibrosis†
by: Anna Serrano-Mollar
Published: (2018-08-01)